Statement Of Cash Flows [Abstract]

Egetis Therapeutics - Filing #678414

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
3,269,000,000 SEK
1,938,000,000 SEK
Adjustments to reconcile profit (loss) [abstract]
Other adjustments for non-cash items
177,000,000 SEK
94,000,000 SEK
Adjustments to reconcile profit (loss)
309,000,000 SEK
109,000,000 SEK
Interest paid, classified as operating activities
41,000,000 SEK
1,000,000 SEK
Interest received, classified as operating activities
49,000,000 SEK
9,000,000 SEK
Income taxes paid (refund), classified as operating activities
1,000,000 SEK
- SEK
Cash flows from (used in) operating activities
2,784,000,000 SEK
1,735,000,000 SEK
Cash flows from (used in) investing activities [abstract]
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities
- SEK
17,000,000 SEK
Purchase of property, plant and equipment, classified as investing activities
0 SEK
- SEK
Cash flows from (used in) investing activities
0 SEK
17,000,000 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
3,819,000,000 SEK
1,774,000,000 SEK
Proceeds from borrowings, classified as financing activities
1,088,000,000 SEK
- SEK
Repayments of borrowings, classified as financing activities
30,000,000 SEK
75,000,000 SEK
Payments of lease liabilities, classified as financing activities
26,000,000 SEK
16,000,000 SEK
Cash flows from (used in) financing activities
4,589,000,000 SEK
1,557,000,000 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
1,804,000,000 SEK
195,000,000 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
48,000,000 SEK
32,000,000 SEK
Cash and cash equivalents
3,033,000,000 SEK
1,277,000,000 SEK
1,440,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.